The reduced expression of the bile salt export pump (BSEP/ ABCB11) at the canalicular membrane is associated with cholestasis-induced hepatotoxicity due to the accumulation of bile acids in hepatocytes. We demonstrated previously that 4-phenylbutyrate (4PBA) treatment, a U.S. Food and Drug Administration-approved drug for the treatment of urea cycle disorders, induces the cell-surface expression of BSEP by prolonging the degradation rate of cell-surface-resident BSEP. On the other hand, BSEP mutations, E297G and D482G, found in progressive familial intrahepatic cholestasis type 2 (PFIC2), reduced it by shortening the degradation rate of cell-surfaceresident BSEP. Therefore, to help the development of the medical treatment of cholestasis, we investigated the underlying mechanism by which 4PBA and PFIC2-type mutations affect the BSEP degradation from cell surface, focusing on shortchain ubiquitination. In Madin-Darby canine kidney II (MDCK II) cells expressing BSEP and rat canalicular membrane vesicles, the molecular mass of the mature form of BSEP/Bsep shifted from 170 to 190 kDa after ubiquitin modification (molecular mass, 8 kDa). Ubiquitination susceptibility of BSEP/Bsep was reduced in vitro and in vivo by 4PBA treatment and, conversely, was enhanced by BSEP mutations E297G and D482G. Moreover, biotin-labeling studies using MDCK II cells demonstrated that the degradation of cell-surface-resident chimeric protein fusing ubiquitin to BSEP was faster than that of BSEP itself. In conclusion, BSEP/Bsep is modified with two to three ubiquitins, and its ubiquitination is modulated by 4PBA treatment and PFIC2-type mutations. Modulation of short-chain ubiquitination can regulate the change in the degradation rate of cell-surfaceresident BSEP by 4PBA treatment and PFIC2-type mutations.
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The bile salt export pump (BSEP/ABCB11) is an ATPbinding cassette transmembrane transporter located in the bile canalicular membrane, playing an indispensable role in the biliary excretion of monovalent bile acids (such as taurocholic acid) (Gerloff et al., 1998; Byrne et al., 2002; Meier and Stieger, 2002; Noe et al., 2002; Trauner and Boyer, 2003; Hayashi et al., 2005b) . The secretion of bile acids into bile by BSEP provides an osmotic driving force for bile formation Trauner and Boyer, 2003) . A hereditary defect of BSEP function results in the acquisition of progressive familial intrahepatic cholestasis type 2 (PFIC2), a fatal liver disease characterized by cholestasis and jaundice in the first year of life (Strautnieks et al., 1998; Jansen et al., 1999) . BSEP function is disrupted not only in PFIC2 but also in several cholestatic models, such as endotoxin-or druginduced cholestasis (Vos et al., 1998; Lee et al., 2000; Elferink et al., 2004) , and cholestasis in pregnancy (Lee et al., 2000; Crocenzi et al., 2003) . In cholestatic patients, it is likely that impaired biliary bile acid secretion causes accumulation of bile acids in hepatocytes and progressive severe hepatocellular damage as a result of the toxicity produced by a high concentration of bile acids. We and other groups have reported that the functional defects of BSEP are often associated with reduced BSEP expression at the canalicular membrane (Vos et al., 1998; Lee et al., 2000; Wang et al., 2002; Crocenzi et al., 2003; Elferink et al., 2004; Plass et al., 2004; Hayashi et al., 2005a; Strautnieks et al., 2008) . Moreover, we found that shortening the half-life of cell-surface-resident BSEP in addition to the proteasome-mediated degradation from the endoplasmic reticulum (ER) are responsible for the reduced cell-surface expression of BSEP in PFIC2 patients with E297G and D482G mutations (Hayashi and Sugiyama, 2007) , both of which are the most frequently found in patients with PFIC2 (Strautnieks et al., 2008) . On the other hand, 4-phenylbutyrate (4PBA), a nontoxic butyrate analog that was originally approved for clinical use as an ammonia scavenger in subjects with urea cycle disorders (Kajimura et al., 1996) , induces cell-surface expression of BSEP by prolonging the half-life of cell-surface-resident BSEP (Hayashi and Sugiyama, 2007) . Its potential therapeutic effect against cholestasis by increasing the cell-surface BSEP expression was identified by us for the first time. Considering that, to date, there are few established medical treatments for severe intrahepatic cholestasis like PFIC2, clarifying the mechanism of BSEP degradation from the canalicular membrane will play an important role in finding new medical treatments for this cholestatic condition, in which the transport function of BSEP is retained. However, this mechanism is not completely understood, although it has been reported that Hax-1 is a binding partner of Bsep and participates in internalization from the apical membrane as demonstrated from an coimmunoprecipitation study using rat canalicular membrane vesicles (rCMVs) and a pulsechase metabolic labeling study using Hax-1-depleted MDCK cells, respectively (Ortiz et al., 2004) .
Ubiquitination is a regulated post-translational modification that conjugates ubiquitin (Ub) to lysine residues of targeted proteins and determines their intracellular fate. The canonical role of ubiquitination is to mediate degradation by the proteasome of the proteins that carry a single or polymeric chain of Ub on a specific lysine residue (d'Azzo et al., 2005) . However, it has been revealed recently that Ub modification has much broader and diverse functions in cellular processes. Short-chain ubiquitination, in which targeted molecules are attached to one or two Ub molecules, has been shown to be involved in the regulation of endocytosis and degradation of receptors, channels, and transporters from the cell surface in yeast (Galan and Haguenauer-Tsapis, 1997) . In higher eukaryotes, this type of ubiquitination enhances endocytosis and lysosomal degradation (Sharma et al., 2004; Lin et al., 2005; Kamsteeg et al., 2006) . Therefore, in the present study, we examined the possibility that 4PBA treatment and PFIC2-type mutations modulate the shortchain ubiquitination, thereby regulating the degradation rate of cell-surface-resident BSEP.
Materials and Methods
Materials. Pharmaceutical-grade 4PBA was purchased from Scandinavian Formulas Inc. (Sellersville, PA). Antibodies against BSEP (N-16) and Ub (P4D1) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-HA antibody (3F10) was obtained from Roche (Indianapolis, IN). Antiserum for rat Bsep (rBsep) was raised in rabbits against an oligopeptide (the carboxyl terminus of rBsep, AYYKLVITGAPIS) (Akita et al., 2001) . All other chemicals were of analytical grade. MDCK II cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 U/ml) at 37°C with 5% CO 2 and 95% humidity.
The cDNAs of BSEP harboring the HA epitope at the N terminus (HA-BSEP) were constructed by PCR involving human BSEP cloned into the pShuttle vector (BD Biosciences, Palo Alto, CA) using the forward primer 5Ј-gagacccaagctggctagcgccgcccccaccatgtacccatacgatgttccagattacgctcttatgtctgactcagtaattcttcgaag-3Ј and the reverse primer 5Ј-cttcgaagaattactgagtcagacataagagcgtaatctggaacatcgtatgggtacatggtgggggcggcgctagccagcttgggtctc-3Ј (BSEP coding sequence in boldface type) (Geiser et al., 2001) . The construct encoding HA-BSEP-Ub ⌬GG , in which the two last Ub glycines were deleted, was obtained by fusing Ub ⌬GG in frame to the C terminus of BSEP using PCR (Geiser et al., 2001) . Mutant chimeras HA-BSEP-Ub ⌬GG/I44A , incorporating Ub I44A in addition to deletion of the last two glycines, were obtained by PCR mutagenesis (Geiser et al., 2001) .
Generation of Recombinant Adenovirus. The BD Adeno-X Adenoviral Expression System (BD Biosciences) was used to create BSEP, E297G BSEP, D482G BSEP, HA-BSEP, HA-BSEP-Ub ⌬GG , and HA-BSEP-Ub ⌬GG/I44A recombinant adenoviruses as described previously (Hayashi et al., 2005a) . The virus titer was quantified with an Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA). As a control, recombinant adenoviruses containing green fluorescence protein (GFP) were used.
Animals. Male Sprague-Dawley (SD) rats (6-7 weeks old) were purchased from Nippon SLC (Shizuoka, Japan). All animals were maintained under standard conditions with a reverse dark-light cycle and were treated humanely. Food and water were available ad libitum. The studies reported in this manuscript were carried out in accordance with the guidelines provided by the Institutional Animal Care Committee (Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan).
Preparation of Canalicular Membrane Vesicles. Male SD rats (6-7 weeks old) were given 0.6 g/kg/day 4PBA or vehicle by gavage in three divided doses for 10 days. rCMVs were prepared from the liver of the treated rats as described previously (Akita et al., 2001) . To inhibit the ubiquitination in vitro, 10 mM N-ethylmaleimide was added to the preparing buffer. Prepared rCMVs were immunoprecipitated.
Immunoprecipitation from rCMVs and MDCK II Cells. Prepared rCMVs (200 g) were solubilized for 1 h at 4°C in 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 10 mM N-ethylmaleimide, and a protease inhibitor cocktail tablet; Roche). The mixtures were centrifuged at 150,000g for 1 h at 4°C. The supernatants were precleared by adding 40 l of protein G-Sepharose beads. MDCK II cells were seeded in 10-cm culture plates at a density of 1.5 ϫ 10 6 cells/plate. After a 24-h culture, confluent cells were infected with recombinant adenovirus containing cDNAs for BSEP, E297G BSEP, D482G BSEP, HA-BSEP, and GFP at a multiplicity of infection of 200. Then, 48 h after the infection, MDCK II cells were solubilized in 1 ml of lysis buffer and precleared by adding 40 l of protein G-Sepharose beads. When isolating the cell-surface-resident BSEP, cell-surface biotinylation was performed as described previously (Hayashi et al., 2005a) before solubilization. The biotinylated cell-surface fraction was isolated with ImmunoPure StreptAvidin (Pierce Biotechnology, Rockford, IL). The prepared specimens were diluted 10-fold with lysis buffer and were subsequently precleared by adding 40 l of protein G-Sepharose beads. Precleared lysates from rCMVs and MDCK II cells and the precleared cell-surface fraction from MDCKII cells were incubated with anti-rBsep antibody (5 g) for 2 h at 4°C. Then, 40 l of protein G-Sepharose beads was added and incubated for 3 h at 4°C. Immune complexes were precipitated, followed by two washes with 1 ml of high-salt buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 10 mM N-ethylmaleimide, 0.1% Nonidet P-40, and 0.05% sodium deoxycholate) and one wash with 1 ml of low-salt buffer (10 mM Tris-HCl, pH 7.5, 10 mM N-ethylmaleimide, 0.1% Nonidet P-40, and 0.05% sodium deoxycholate). Immunoprecipitated proteins were eluted for 5 min at 100°C with 50 l of 1 ϫ Reducing Loading Buffer (New England Biolabs, Ipswich, MA). The specimens were separated by 6% SDS-PAGE and subjected to Western blot analysis.
Cleavage of Glycosylation. To examine the extent of glycosylation of ubiquitinated BSEP, 20 l of immunoprecipitated specimens was digested with endoglycosidase H (EndoH; New England Biolabs) or peptide N-glycosidase F (PNGaseF; New England Biolabs) at 37°C for 2 h as described by the manufacturer. The deglycosylated proteins were separated by 6% SDS-PAGE and subjected to Western blot analysis.
Western Blot Analysis. Specimens were loaded onto a 6% SDS-PAGE plate with a 3.75% stacking gel and subjected to Western blot analysis with 300-fold diluted polyclonal BSEP antibody (N-16), 1000-fold diluted monoclonal HA antibody (3F10), and 300-fold diluted monoclonal Ub antibody (P4D1) as described previously (Hayashi et al., 2005a) . Immunoreactivity was detected with an ECL Advance Western Blotting Detection Kit (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). The intensity of the band indicating the short-chain ubiquitinated BSEP and mature form of BSEP was quantified by Multi Gauge software version 2.0 (Fujifilm, Tokyo, Japan).
Cell-Surface Biotinylation and Determination of Degradation Rate of Cell-Surface Expressing Protein. MDCK II cells were seeded on 12-well plates at a density of 2.5 ϫ 10 5 cells/well. After a 24-h culture, confluent cells were infected with recombinant adenovirus containing cDNAs for HA-BSEP, HA-BSEP-Ub ⌬GG , HA-BSEP-Ub ⌬GG/I44A , and GFP at a multiplicity of infection of 200. Then, 24 h after infection, cell-surface biotinylation was performed as described previously (Hayashi et al., 2005a) .
To examine the degradation rate of the cell-surface-resident protein, biotinylated MDCK II cells were incubated for various periods at 37°C before solubilization. Then, the remaining biotinylated protein was isolated as described above, separated by 6% SDS-PAGE, and subjected to Western blot analysis.
Statistical Analysis. Experiments were repeated at least three times, and graphs include means Ϯ S.E. P values between two variables and multiple variables were calculated at the 95% confidence level with Student's t test and analysis of variance, respectively, using Prism software (GraphPad Software, Inc., San Diego, CA).
Results

Ubiquitination of BSEP/Bsep in Vitro and in Vivo.
To investigate whether BSEP is ubiquitinated in MDCK II cells, it was immunoprecipitated from MDCK II cells expressing HA-BSEP with rBsep antibody (Fig. 1A) . Subsequent Western blot analysis for Ub and HA detected a ubiquitinated BSEP band at a molecular mass of 190 kDa (Fig. 1A, top) and two BSEP bands of 150 and 170 kDa, respectively (Fig. 1A , bottom). Its ubiquitinated BSEP band was also detected in immunoprecipitates prepared from the cell-surface fraction of MDCK II cells with rBsep antibody (Fig. 1B, top) . In these immunoprecipitates, BSEP was detected as only the 170-kDa band (Fig. 1B, bottom) . The ubiquitination of Bsep was confirmed in vivo. In immunoprecipitates from rCMVs with rBsep antibody, ubiquitinated Bsep and Bsep were detected as a smear band around 190 kDa (Fig. 1C, top) and only the 170-kDa band (Fig. 1C, bottom) , respectively.
Ubiquitinated BSEP was sensitive to PNGaseF, which cleaves the high mannose-and complex-type sugar chains, but was insensitive to EndoH, which does not cleave these sugar chains (Fig. 1D, top) , indicating that the N-glycans attached to ubiquitinated BSEP were highly modified in the Golgi complex. Ubiquitinated Bsep was also sensitive to PNGaseF and insensitive to EndoH (data not shown). These results suggest that these ubiquitinated BSEP/Bsep represent the attachment of Ub to the mature form of BSEP/Bsep and do not represent the intermediate form of the polyubiquitinated immature BSEP/Bsep in the ER. In addition, EndoH digestion of immunoprecipitated BSEP resulted in a shift of the 150-kDa band but not the 170-kDa band (Fig. 1D,  bottom) , suggesting that the 150-and 170-kDa bands represent the immature ER-resident form and the mature form of BSEP, respectively. This indication is further supported from the results showing that the cell-surface-resident BSEP in MDCKII cells was detected as only the 170-kDa band (Fig.  1B, bottom) , and Bsep in rCMVs, which are the canalicular membrane-enriched fraction, was also detected as only the 170-kDa band (Fig. 1C, bottom) . Considering that the molecular masses of the ubiquitinated BSEP/Bsep, the mature form of BSEP/Bsep and Ub, are 190, 170, and 8 kDa, respectively, this shows that BSEP/Bsep can be modified with two to three Ub molecules at steady state.
Alteration of Short-Chain Ubiquitination Susceptibility of BSEP by PFIC2-Type Mutations and 4PBA Treatment. We reported previously that E297G and D482G, frequent mutations in PFIC2 patients, shorten the half-life of cell-surface-resident BSEP by approximately 1.5-and 4-fold, respectively, and, conversely, 4PBA treatment prolongs cellsurface-resident BSEP 2-fold (Hayashi and Sugiyama, 2007) . To explore a possible correlation between the half-life of cellsurface-resident BSEP and the short-chain ubiquitination susceptibility of BSEP, mutated BSEP was immunoprecipitated from MDCK II cells expressing E297G BSEP and D482G BSEP, and the immunoprecipitates were subjected to Western blot analysis for Ub and BSEP ( Fig. 2A) . BSEP, E297G BSEP, and Bsep were also immunoprecipitated from MDCK II cells expressing BSEP and E297G BSEP after 4PBA treatment and rCMVs prepared from 4PBA-treated SD rats, and the immunoprecipitates were subjected to Western blot analysis for Ub and BSEP (Fig. 3, A-C) . Quantitative densitometry analysis revealed that the ratio of the shortchain ubiquitinated BSEP, PFIC2-type mutated BSEPs (Figs. 2A and 3, A and B, arrow) to the mature form of BSEP, PFIC2-type mutated BSEPs (Figs. 2A and 3, A and B, filled arrowhead) was significantly greater, 6-and 30-fold by E297G and D482G mutations, respectively, than that in wild-type BSEP (Fig. 2B) , and was reduced in a time-dependent manner after 4PBA treatment in vitro (Fig. 3, D and E) . The same 4PBA effect was also observed in vivo (Fig. 3C ). This ratio was reduced 5-fold after 4PBA treatment for 10 days (Fig. 3F) . Fig. 2 . The effect of PFIC2-type mutations on short-chain ubiquitination of BSEP. A, short-chain ubiquitination susceptibility of PFIC2-type mutated BSEPs, E297G BSEP and D482G BSEP. BSEP and PFIC2-type mutated BSEPs were immunoprecipitated from MDCK II cells expressing BSEP, PFIC2-type mutated BSEPs, and GFP with anti-rBsep antibody. Immunoprecipitates (15 and 30 l) were separated by 6% SDS-PAGE and subjected to Western blot analysis. Arrow, filled and open arrowheads indicate the short-chain ubiquitinated BSEP, the mature and immature forms of BSEP, respectively. B, quantification of the short-chain ubiquitinated BSEP normalized with regard to the mature form of BSEP in A. Data are derived from the intensity of the band indicating the short-chain ubiquitinated BSEP and the mature form of BSEP from 15 l of each specimen applied. Band density was quantified by Image Gauge software. Open, gray, and closed columns represent the ratio of band density indicating the short-chain ubiquitinated BSEP to that indicating the mature form of BSEP in MDCK II cells expressing BSEP, E297G BSEP, and D482G BSEP, respectively. Each bar represents the mean Ϯ S.E., n ϭ 3 to 4. Asterisks represent statistically significant differences between BSEP and mutated BSEP, ‫,ء‬ P Ͻ 0.05, and ‫,ءء‬ P Ͻ 0.01.
Degradation Rate of Cell-Surface-Resident BSEP-Ub Chimera. To directly examine the effect of short-chain ubiquitination on the degradation rate of cell-surface-resident BSEP, MDCK II cells expressing a protein fusion of Ub ⌬GG or Ub ⌬GG/I44A to the BSEP were constructed (Fig. 4A) . Because the Ub chain is extended via covalent binding between the glycine residues in the C terminus and lysine residues, the fusion protein of Ub ⌬GG mimics the effect of the attachment of a Ub (Haglund et al., 2003; Kamsteeg et al., 2006 ). An epidermal growth factor receptor (EGFR)-Ub ⌬GG was actually detected in only monoubiquitinated form, although EGFR-Ub chimera protein containing wild-type Ub was detected as not only the monoubiquitinated form but also the polyubiquitinated form (Haglund et al., 2003) . The I44A mutation in Ub has been shown to inhibit the interaction of Ub with Ub-binding adaptor proteins, which recruits certain ubiquitinated cell-surface receptors for lysosomal degradation (Shih et al., 2002; Sharma et al., 2004; Stang et al., 2004) . In the previous article examining the effect of ubiquitination on the degradation of cystic fibrosis transmembrane conductance regulator (CFTR) from the cell surface, it was demonstrated that the I44A mutation inhibited the interaction of Ub with hepatocyte growth factor-regulated tyrosine kinase substrate, the primary Ub-binding adaptor that forms the sorting complex involving components of the endosomal sorting complex required for transport I, and consequently, the lysosomal degradation of CFTR-Ub ⌬GG/I44A was prevented in comparison with CFTR-Ub ⌬GG , and the degradation rate of CFTR-Ub ⌬GG/I44A was equivalent to that of CFTR itself (Sharma et al., 2004) . Therefore, the fusion of Ub ⌬GG/I44A to BSEP has been used as a negative control to examine only the effect of covalent binding of a Ub. Biotin-labeling studies using MDCK II cells expressing HA-BSEP, HA-BSEPUb ⌬GG , and HA-BSEP-Ub ⌬GG/I44A demonstrated that fusion Immunoprecipitates were separated by 6% SDS-PAGE and subjected to Western blot analysis. Arrows, filled arrowheads, and open arrowheads indicate the short-chain ubiquitinated BSEP and the mature and immature forms of BSEP, respectively. C, short-chain ubiquitination susceptibility of Bsep in 4PBA-treated SD rats. Male SD rats (6 -7 weeks old) were given 4PBA or vehicle by gavage for 10 days at 0.6 g/kg/day before the experiments. Bsep was immunoprecipitated from solubilized rCMVs prepared from 4PBA-treated SD rats with anti-rBsep antibody. Immunoprecipitates were separated by 6% SDS-PAGE and subjected to Western blot analysis. D and E, quantification of the short-chain ubiquitinated BSEP and E297G BSEP normalized with regard to the mature form of BSEP and E297G BSEP in A and B. Data are derived from the band density indicating the short-chain ubiquitinated BSEP and mature form of BSEP by Image Gauge software. Each bar represents the mean Ϯ S.E., n ϭ 3. F, quantification of the short-chain ubiquitinated Bsep normalized with regard to Bsep in C. Data are derived from the intensity of the band indicating the short-chain ubiquitinated Bsep and Bsep by Image Gauge software. Closed and open columns represent the ratio of band density indicating the short-chain ubiquitinated Bsep to Bsep in rCMVs prepared from SD rats, with and without 4PBA, respectively. Each bar represents the mean Ϯ S.E., n ϭ 4. Asterisks represent statistically significant differences between vehicle-treated SD rats and 4PBA-treated SD rats, ‫,ءء‬ P Ͻ 0.01.
Short-Chain Ubiquitination of BSEP/Bsep 147
at ASPET Journals on October 14, 2017 molpharm.aspetjournals.org
Downloaded from
of Ub ⌬GG shortened the half-life of cell-surface-resident BSEP 2.5-fold, whereas that of Ub ⌬GG/I44A had no effect (Fig.  4, B and C) .
Discussion
The reduction of BSEP expression at the canalicular membrane causes or aggravates cholestasis (Vos et al., 1998; Lee et al., 2000; Wang et al., 2002; Crocenzi et al., 2003; Elferink et al., 2004; Plass et al., 2004; Hayashi et al., 2005a) . We have found previously that shortening the half-life of cell-surfaceresident BSEP is partly responsible for the reduced cell surface expression of BSEP in patients with PFIC2 with E297G and D482G mutations (Hayashi and Sugiyama, 2007) . Moreover, 4PBA is a potential therapeutic agent to combat cholestasis, the effect of which induces cell-surface expression of BSEP by prolonging the degradation rate of cell-surfaceresident BSEP (Hayashi and Sugiyama, 2007) . Therefore, it is considered that elucidating the regulatory mechanism of BSEP degradation from the cell surface will help to establish a new medical treatment for cholestasis. However, its mechanism is poorly understood. In the present study, we examined the possibility that 4PBA treatment and PFIC2-type mutations modulate the short-chain ubiquitination, thereby regulating the degradation rate of cell-surfaceresident BSEP.
Initially, ubiquitination of BSEP/Bsep in vitro and in vivo was confirmed by immunoprecipitation of protein obtained from MDCK II cells expressing BSEP and rCMVs (Fig. 1, A and C). The ubiquitinated BSEP was also detected in the surface fraction (Fig. 1B) . The ubiquitinated BSEP was sensitive to PNGaseF and insensitive to EndoH (Fig. 1D) . Considering that the molecular masses of the mature form of BSEP/Bsep and Ub are 170 and 8 kDa, respectively, it was found that BSEP/Bsep can be modified with two to three Ub molecules at a steady state. Although the bands corresponding to the ubiquitinated BSEP/Bsep (ϳ190 kDa) were not detected by both HA antibody and BSEP antibody (Fig. 1,  A-C) , it may be accounted by the low amount of the ubiquitinated BSEP/Bsep compared with nonubiquitinated BSEP/ Bsep. This interpretation is supported by recent studies showing that the amount of monoubiquitinated ROMK1 and short-chain ubiquitinated aquaporin-2 water channel (AQP2) were much lower than that of the nonubiquitinated form (Lin et al., 2005; Kamsteeg et al., 2006) . In the case of AQP2, similar to BSEP/Bsep, short-chain ubiquitinated AQP2 in immunoprecipitates produced by AQP2 antibody were not detected by AQP2 antibody (Kamsteeg et al., 2006) .
Next, the alteration in short-chain ubiquitination susceptibility was investigated to analyze the correlation with the degradation rate of BSEP from the cell surface. Quantitative densitometry analysis revealed PFIC2-type mutations, which shorten the half-life of cell-surface-resident BSEP (Hayashi and Sugiyama, 2007) , induce the shortchain ubiquitination of BSEP, and conversely, 4PBA treatment, which prolongs the half-life of cell-surface-resident BSEP (Hayashi and Sugiyama, 2007) , reduced it in vitro and in vivo (Figs. 2 and 3) , indicating a correlation between the half-life of cell-surface-resident BSEP with the ubiquitination propensity of BSEP. Moreover, the effect of short-chain ubiquitination on BSEP degradation was directly investigated using MDCK II cells expressing HA-BSEP-Ub 
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Hayashi and Sugiyama at ASPET Journals on October 14, 2017 molpharm.aspetjournals.org whereas that of Ub ⌬GG/I44A , as a negative control, had no effect, suggesting that the short-chain ubiquitination promotes the degradation of BSEP from the cell surface (Fig.  4 , B and C). This suggestion is further supported by the finding that the ubiquitinated BSEP is actually present at the cell surface (Fig. 1B) .
Although it has been reported that short-chain ubiquitination of receptors and channels promotes endocytosis from the cell surface (Haglund et al., 2003; Kamsteeg et al., 2006) and/or translocation from the endosomal compartment to lysosomes (Haglund et al., 2003; Sharma et al., 2004) , the regulation of transporters by short-chain ubiquitination has not been clarified in detail in higher eukaryotes. To our knowledge, this is the first reported example in an ATPbinding cassette-type transporter in higher eukaryotes that BSEP/Bsep can be attached to Ub, and its ubiquitination relates to the promotion of degradation from the cell surface. It remains unclear whether the accelerated degradation of cell-surface-resident BSEP by short-chain ubiquitination results from the promotion of the endosomal sorting from the cell surface or the delivery from the endosomal compartment to lysosomes, or both. However, a recent report suggesting that epidermal-growth factor receptor pathway substrate 15 (Eps15) is involved in endocytosis of Bsep (Ortiz et al., 2004) may provide several clues to the role of short-chain ubiquitination in BSEP sorting. Eps15 contains various functional regions, three Eps15 homology domains that interact with proteins containing tandem asparagine, proline, and phenylalanine repeats in the N-terminal domain, binding sites to the ␣-subunit of the clathrin adaptor-protein complex activator protein-2 and two ubiquitin-interacting motifs at the C-terminal domain (Regan-Klapisz et al., 2005) . Considering that Eps15 could be involved in the initial steps of clathrincoated pit formation through the Eps15 homology domain-NPF motif interaction (Morgan et al., 2003) and recruit ubiquitinated receptors from the plasma membrane through its ubiquitin-interacting motifs (de Melker et al., 2004; Polo et al., 2002) , it is possible that the short-chain ubiquitination escorts BSEP into the forming clathrin-coated pit.
Here, we demonstrated that BSEP/Bsep can be modified by two to three Ub molecules, and its ubiquitination promotes the degradation of cell-surface-resident BSEP. The ubiquitination of substrate proteins are performed by covalent attachment of Ub via the sequential action of three enzymes: a Ub-activating enzyme E1, a Ub-conjugating enzyme E2, and a Ub ligase E3 (Hershko et al., 2000; d'Azzo et al., 2005) . Among these three enzymes, E3s are considered to ensure the correct timing, localization, and specificity of the ubiquitination reaction, because genomic information suggests that there are several hundreds of E3s in eukaryotic cells. Therefore, the E3 responsible for the short-chain ubiquitination of BSEP is an attractive target for treatment of severe cholestatic disease. Moreover, it has also been demonstrated that E3s are regulated by various mechanisms, including protein-protein interactions and phosphorylation (d'Azzo et al., 2005) . For example, autophosphorylation of EGFR by ligand binding promotes its recognition by Ring-type E3, Casitas B-lineage lymphoma (Rubin et al., 2005) , whereas its Casitas B-lineage lymphoma-EGFR interaction is negatively regulated by protein-protein interaction with Sprouty (d'Azzo et al., 2005) . In future studies, the identification of the E3s, which participate in the short-chain ubiquitination of BSEP, and the elucidation of its regulatory mechanism will help in the development of new medical treatments for severe cholestasis.
In conclusion, the results of the present study demonstrate that BSEP/Bsep is modified with two to three ubiquitins, and its ubiquitination is modulated by 4PBA treatment and PFIC2-type mutations. Modulation of short-chain ubiquitination can regulate the change in the degradation rate of cell-surface-resident BSEP by 4PBA treatment and PFIC2-type mutations. These pieces of information should be useful in understanding the pathogenic mechanism of severe cholestasis related to reduced BSEP expression at the canalicular membrane and will help in the development of new medical treatments for severe cholestasis.
